Long-term experiences with high-energy shock wave therapy in the management chronic phase Peyronie's disease using two different electromagnetic lithotripters.
Extracorporeal shock wave therapy
High-intensity ESWT
Induratio penis plastica
Low-intensity ESWT
Non-surgical treatment options
Peyronie’s disease, acute and chronic phase
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
07 Mar 2024
07 Mar 2024
Historique:
received:
29
06
2023
accepted:
16
01
2024
medline:
8
3
2024
pubmed:
8
3
2024
entrez:
7
3
2024
Statut:
epublish
Résumé
Extracorporeal shock wave lithotripsy represents one option for the non-surgical management of Peyronie's disease. Despite promising results, several questions are still pending. We want to present the long-term results of a retrospective study using high-energy extracorporeal shock wave lithotripsy. We evaluated retrospectively 110 patients treated between 1996 and 2020 at the Department of Urology, SLK Kliniken Heilbronn for chronic phase Peyronie's disease using two electromagnetic lithotripters (Siemens Lithostar Plus Overhead Module, Siemens Lithoskop) applying high-energy shock waves under local anesthesia and sonographic or fluoroscopic control. A standardized questionnaire focused on the change in pain, curvature, sexual function and the need of penile surgery. In 85 of the 110 patients (mean age 54 years) we had sufficient data for evaluation. The median follow-up was 228 (6-288) months. There were no significant complications. Pain reduction was achieved in all patients, 65 (76%) patients were free of pain. Improvement of penile curvature was achieved in 43 patients (51%) ranging from 25% improvement (deflected angle < 30°) to 95% (angle 30-60°). 59 patients (69%) reported problems with sexual intercourse, 40 of those (68%) reported improvement. Only 9 (10.5%) patients underwent surgical correction. We did not observe any significant differences between both electromagnetic devices with stable long-term results. High-energy shock wave therapy delivered by two standard electromagnetic lithotripters is safe and efficient providing stable long-term results. In cases with significant plaque formation, the concept of high-energy ESWT should be considered in future studies.
Sections du résumé
BACKGROUND
BACKGROUND
Extracorporeal shock wave lithotripsy represents one option for the non-surgical management of Peyronie's disease. Despite promising results, several questions are still pending. We want to present the long-term results of a retrospective study using high-energy extracorporeal shock wave lithotripsy.
MATERIAL AND METHODS
METHODS
We evaluated retrospectively 110 patients treated between 1996 and 2020 at the Department of Urology, SLK Kliniken Heilbronn for chronic phase Peyronie's disease using two electromagnetic lithotripters (Siemens Lithostar Plus Overhead Module, Siemens Lithoskop) applying high-energy shock waves under local anesthesia and sonographic or fluoroscopic control. A standardized questionnaire focused on the change in pain, curvature, sexual function and the need of penile surgery.
RESULTS
RESULTS
In 85 of the 110 patients (mean age 54 years) we had sufficient data for evaluation. The median follow-up was 228 (6-288) months. There were no significant complications. Pain reduction was achieved in all patients, 65 (76%) patients were free of pain. Improvement of penile curvature was achieved in 43 patients (51%) ranging from 25% improvement (deflected angle < 30°) to 95% (angle 30-60°). 59 patients (69%) reported problems with sexual intercourse, 40 of those (68%) reported improvement. Only 9 (10.5%) patients underwent surgical correction. We did not observe any significant differences between both electromagnetic devices with stable long-term results.
CONCLUSIONS
CONCLUSIONS
High-energy shock wave therapy delivered by two standard electromagnetic lithotripters is safe and efficient providing stable long-term results. In cases with significant plaque formation, the concept of high-energy ESWT should be considered in future studies.
Identifiants
pubmed: 38453751
doi: 10.1007/s00345-024-04792-x
pii: 10.1007/s00345-024-04792-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
124Informations de copyright
© 2024. The Author(s).
Références
Bilgutay AN, Pastuszak AW (2015) Peyronie’s disease: a review of etiology, diagnosis, and management. Curr Sex Health Rep 7:117–131
doi: 10.1007/s11930-015-0045-y
Salonia A, Bettocchi C, Boeri L, Capogrosso P, Carvalho J, Cilesiz NC, Cocci A, Corona G, Dimitropoulos K, Gül M, Hatzichristodoulou G, Jones TH, Kadioglu A, Martínez Salamanca JI, Milenkovic U, Modgil V, Russo GI, Serefoglu EC, Tharakan T, Verze P, Minhas S, EAU Working Group on Male Sexual and Reproductive Health (2021) European Association of Urology Guidelines on Sexual and Reproductive Health-2021 update: male sexual dysfunction. Eur Urol 80:333–357
doi: 10.1016/j.eururo.2021.06.007
Di Maida F, Cito G, Lambertini L, Valastro F, Morelli G, Mari A, Carini M, Minervini A, Cocci A (2021) The natural history of Peyronie’s disease. World J Mens Health 39(3):399–405
doi: 10.5534/wjmh.200065
Cocci A, Russo GI, Martinez-Salamanca JI, Ralph D, Djinovic R, Şerefoğlu EC, Mondaini N (2022) Is there a line between ethics and market competition? Lights and shades of the withdrawal of collagenase treatment for Peyronie’s disease. Int J Impot Res 34(8):733–734
doi: 10.1038/s41443-021-00469-w
Abdel-Salam Y, Budair Z, Renner C, Frede T, Rassweiler J, El-Annany F, El-Magraby H, El-Akkad M (1999) Treatment of Peyronie’s disease by extracorporeal shockwave therapy: evaluation of our preliminary results. J Endourol 13:549–552
doi: 10.1089/end.1999.13.549
Mirone V, Imbimbo C, Palmieri A, Fusco F (1999) Our experience on the association of a new physical and medical therapy in patients suffering from induratio penis plastica. Eur Urol 36(4):327–330. https://doi.org/10.1159/000020013 . (PMID: 10473993)
doi: 10.1159/000020013
Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F, Creta M, Mirone V (2009) A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie’s disease. Eur Urol 56:363–369
doi: 10.1016/j.eururo.2009.05.012
Chitale S, Morsey M, Swift L, Sethia K (2010) Limited shock wave therapy vs sham treatment in men with Peyronie’s disease: results of a prospective randomized controlled double-blind trial. BJU Int 106:1352–1356
doi: 10.1111/j.1464-410X.2010.09331.x
Hatzichristodoulou G, Meisner C, Gschwend JE, Stenzl A, Lahme S (2013) Extracorporeal shock wave therapy in Peyronie’s disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med 1:2815–2821
doi: 10.1111/jsm.12275
Lebret T, Loison G, Hervé JM, Mc Eleny KR, Lugagne PM, Yonneau L, Orsoni JL, Saporta F, Butreau M, Botto H (2002) Extracorporeal shock wave therapy in the treatment of Peyronie’s disease: experience with standard lithotriptor (siemens-multiline). Urology 59:657–661
doi: 10.1016/S0090-4295(02)01527-3
Kiyota H, Ohishi Y, Asano K, Hasegawa N, Madarame J, Miki K, Kato N, Kimura T, Ishiyama T, Maeda S, Shimomura T, Shiono Y, Miki J (2002) Extracorporeal shock wave treatment for Peyronie’s disease using EDAP LT-02; preliminary results. Int J Urol 9:110–113
doi: 10.1046/j.1442-2042.2002.00430.x
De Berardinis E, Busetto GM, Antonini G, Giovannone R, Gentile V (2010) Extracorporeal shock wave therapy in the treatment of Peyronie’s disease: long-term results. Arch Ital Urol Androl 82:128–133
Michel MS, Ptaschnyk T, Musial A, Braun P, Lenz ST, Alken P, Köhrmann KU (2003) Objective and subjective changes in patients with Peyronie’s disease after management with shock wave therapy. J Endourol 17:41–44
doi: 10.1089/089277903321196788
Strebel RT, Suter S, Sautter T, Hauri D (2004) Extracorporeal shockwave therapy for Peyronie’s disease does not correct penile deformity. Int J Impot Res 16:448–451
doi: 10.1038/sj.ijir.3901192
Hauck EW, Hauptmann A, Bschleipfer T, Schmelz HU, Altinkilic BM, Weidner W (2004) Questionable efficacy of extracorporeal shock wave therapy for Peyronie’s disease: results of a prospective approach. J Urol 171:296–299
doi: 10.1097/01.ju.0000099891.68488.4e
Shimpi RK, Jain RJ (2016) Role of extracorporeal shock wave therapy in management of Peyronie’s disease: a preliminary report. Urol Ann 8:409–417
doi: 10.4103/0974-7796.192100
Rassweiler J (2018) Re: Extracorporeal shock wave therapy (ESWT) in Urology: a systematic review of outcome in Peyronie’s disease, erectile dysfunction, and chronic pain (Words of Wisdom). Eur Urol 74:115–117
doi: 10.1016/j.eururo.2018.01.037
Fojecki GL, Tiessen S, Osther PJ (2017) Extracorporeal shock wave therapy (ESWT) in urology: a systematic review of outcome in Peyronie’s disease, erectile dysfunction and chronic pelvic pain. World J Urol 35:1–9
doi: 10.1007/s00345-016-1834-2
Srirangam SJ, Manikandan R, Hussain J, Collins GN, O’Reilly PH (2006) Long-term results of extracorporeal shockwave therapy for Peyronie’s disease. J Endourol 20:880–884
doi: 10.1089/end.2006.20.880
Sokolakis I, Pyrgidis N, Lahme S, Hatzichristodoulou G (2022) Low-intensity shockwave therapy in Peyronie’s disease: long-term results from a prospective, randomized, sham-controlled trial. Int J Impot Res 34:487–494
doi: 10.1038/s41443-021-00447-2
Spirito L, Manfredi C, La Rocca R, Napolitano L, Preto M, Di Girolamo A, Arcaniolo D, De Sio M, Creta M, Longo N (2023) Long-term outcomes of extracorporeal shock wave therapy for acute Peyronie’s disease: a 10-year retrospective analysis. Int J Impot Res. https://doi.org/10.1038/s41443-023-00673-w
doi: 10.1038/s41443-023-00673-w
Coyne KS, Currie BM, Thompson CL, Smith TM (2015) The test-retest reliability of the Peyronie’s disease questionnaire. J Sex Med 12:543–548
doi: 10.1111/jsm.12769
Seemann O, Rassweiler J, Chvapil M, Alken P, Drach GW (1992) Effect of low dose shock wave energy on fracture healing: an experimental study. J Endourol 6:219
doi: 10.1089/end.1992.6.219
Haupt G, Haupt A, Ekkernkamp A, Gerety B, Chvapil M (1992) Influence of shock wave on wound-healing. Urology 39:529–532
doi: 10.1016/0090-4295(92)90009-L
Rompe JD, Hopf C, Nafe B, Burger R (1996) Low-energy extracorporeal shock wave therapy for painful heel: a prospective controlled single-blind study. Arch Orthop Trauma Surg 115:75–79
doi: 10.1007/BF00573445
Porst H (2021) Review of the current status of low intensity extracorporeal shockwave therapy (Li-ESWT) in erectile dysfunction (ED), Peyronie’s disease (PD), and sexual rehabilitation after radical prostatectomy with special focus on technical aspects of the different marketed ESWT devices including personal experiences in 350 patients. Sex Med Rev 9:93–122
doi: 10.1016/j.sxmr.2020.01.006
Abdessater M, Akakpo W, Kanbar A, Parra J, Seisen T, Chartier-Kastler E, Drouin SJ, Roupret M (2022) Low-intensity extracorporeal shock wave therapy for Peyronie’s disease: a single-center experience. Asian J Androl 24:45–49
doi: 10.4103/aja.aja_40_21
Mirone V, Imbimbo C, Palmieri A, Longo N, Fusco F, Tajana G (2002) A new biopsy technique to investigate Peyronie’s disease associated histologic alterations: results with two different forms of therapy. Eur Urol 42:239–244
doi: 10.1016/S0302-2838(02)00225-7
Zhang X, Ruan Y, Wu AK, Zaid U, Villalta JD, Wang G, Banie L, Reed-Maldonado AB, Lin G, Lue TF (2020) Delayed treatment with low-intensity extracorporeal shock wave therapy in an irreversible rat model of stress urinary incontinence. Urology 141:187.e1-187.e7
doi: 10.1016/j.urology.2020.03.035
Rassweiler JJ, Scheitlin W, Goezen AS, Rassweiler-Seyfried MC (2022) Low-energy shockwave therapy in the management of wound healing following Fournier’s Gangrene. Eur Urol Open Sci 13(45):8–11
doi: 10.1016/j.euros.2022.08.019